| Literature DB >> 35423538 |
Javad Esmaeili1,2, Abolfazl Barati1, Jafar Ai3, Vajihe Taghdiri Nooshabadi3,4, Zeynab Mirzaei5,2.
Abstract
Cancer is a complicated disease that involves the efforts of researchers to introduce and investigate novel successful treatments. Traditional cancer therapy approaches, especially chemotherapy, are prone to possible systemic side effects, such as the dysfunction of liver or kidney, neurological side effects and a decrease of bone marrow activity. Hydrogels, along with tissue engineering techniques, provide tremendous potential for scientists to overcome these issues through the release of drugs at the site of tumor. Hydrogels demonstrated competency as potent and stimulus-sensitive drug delivery systems for tumor removal, which is attributed to their unique features, including high water content, biocompatibility, and biodegradability. In addition, hydrogels have gained more attention as 3D models for easier and faster screening of cancer and tumors due to their potential in mimicking the extracellular matrix. Hydrogels as a reservoir can be loaded by an effective dosage of chemotherapeutic agents, and then deliver them to targets. In comparison to conventional procedures, hydrogels considerably decreased the total cost, duration of research, and treatment time. This study provides a general look into the potential role of hydrogels as a powerful tool to augment cancer studies for better analysis of cancerous cell functions, cell survival, angiogenesis, metastasis, and drug screening. Moreover, the upstanding application of drug delivery systems related to the hydrogel in order to sustain the release of desired drugs in the tumor cell-site were explored. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35423538 PMCID: PMC8695814 DOI: 10.1039/d1ra00855b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1Components of the tumor microenvironment.[3]
A summary of hydrogel applications in cancer therapy
| Type of cancer | Cell | Polymer (hydrogel) | approach | subject under study | Drug | Reference | Year |
|---|---|---|---|---|---|---|---|
| Breast | Stromal cell MCF-7 cells | Gelatin collagen | 3D model in vitro | Behaviour of breast cancer cells in response to different environmental stimuli | — |
| 2015 |
| Breast | Human umbilical vein endothelial cells (HUVECs) | Carbon dots, polyethylene glycol, folic acid | Organ-on-chip | To rapidly screen drugs and drug delivery systems | Doxorubicin (DOX) |
| 2018 |
| Breast | MCF-7 | PEGylated fluorocarbon nanoparticles, PEGylated hydrocarbon nanoparticles | Drug delivery system | Simultaneous and segregated delivery of multiple drugs | PTX-DOX |
| 2015 |
| Skin | Oral squamous cell carcinoma (D20 and Cal27 cells) | Collagen | 3D model | Generate tissue-engineered models and compared with patient biopsies | — |
| 2011 |
| Melanoma | Cell lines. B16.F10 mouse melanoma cells | Matrigel | 3D tissue model (rotating wall vessel bioreactor system) | Cell interactions and collection of new information about cancer development | — |
| 2009 |
| Prostate | M12 and LNCaP C4-2 | poly(2-hydroxyethyl methacrylate) | Hydrogel | Describe a capillary force-based method for seeding the human prostate cancer cell lines | — |
| 2013 |
| Prostate | Human PCa cells (LNCaP, C4-2, and C4-2B) | Matrigel matrix and chitosan–alginate | 3D model | A new matrix for studying prostate cancer cell-lymphocyte interactions | — |
| 2012 |
| Liver | HepG2 (human HCC cell line) | Co-polyester polymer (Zimmer and Peacock,92000042) | 3D printing | Real-time immunodetection of liver cancer cells | — |
| 2017 |
| Liver | Human hepatocellular carcinoma cells (FLC-4 cells) | Tetra ethoxysilane, poly- dimethylsiloxane, galactosylated silk fibroin -based, collagen | 3D scaffold | A hepatic tissue engineering application of three-dimensional (3D) poroussponges | — |
| 2011 |
| Brain | Glioma (D54 and D54-GFP-luc) cell lines | Chitosan alginate | Hydrogel ( | Injectable hydrogels for localized chemotherapy and radiotherapy in brain tumors | — |
| 2018 |
| Brain | Glioma stem cell | Gelatin/alginate/fibrinogen | 3D bioprinting | Glioma genesis and drug resistance | — |
| 2016 |
| Lung | H1975 human NSCLC adenocarcinoma cells, human primary airway epithelial cells, human lung microvascular endothelial cells | Poly-dimethylsiloxane (PDMS), gelatin, polyester (polyethylene terephthalate [PET]) | Organ-on-chip | To create | Tyrosine kinase inhibitor |
| 2017 |
| Bladder | Fibroblasts and urothelial cells (RT4 (NMIBC) and T24 (MIBC) cell lines) | Gelatin collagen | 3D model | Reconstitution of the microenvironment | — |
| 2017 |
| Glioblastoma | Astrocytes | Lauroyl-gemcitabine lipid (GemC12-LNC) | Nanodelivery of drugs | Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment | Paclitaxel (PTX) |
| 2019 |
| Solid tumors | HeLa cells | mPECT(D)/GDDC-4(R)/α-CD | Drug delivery system | Co-delivery of drugs and siRNA | GDDC-4/siRNA |
| 2019 |
| Prostate | DU-145 cells and PC-3 cells | Two zinc ions (ZIs)-responsive short peptide dendrons (E3FID and E3FNP) hydrogels | Drug delivery system | Conjugation of forky peptides and nonsteroidal anti-inflammatory drugs (NSAID) self-assemble into supramolecular hydrogels | Docetaxel (DTX) |
| 2019 |
| Head and neck | HSC-3 cells | Self-assembling peptide | Drug delivery system | Local Co-delivery of drugs | Doxorubicin and curcumin |
| 2019 |
| Breast | TNBCs | RNA-triple helix | Drug delivery system | Incorporating the RNA-triple-helix and siRNA duplexes of CXCR4 into the same RNA nanoparticles | miRNA-205, miRNA-221 |
| 2020 |
| Breast | MCF-7 cells | Hyaluronic acid | 3D model | Mimicking extracellular matrix | — |
| 2019 |
Fig. 2(a–f) Computed tomography scans (CTS) before (a, c, e) and after (b, d, f) hydrogel spacer injection between the HOP and duodenum.[67] (g–i) MRI image of a spacer patient at baseline (g), post-application (h), and 12 months after spacer application (i).[65] (j) The way of spacer injection (PEG hydrogel spacer injection) between the prostate and rectal wall.[59] (k) Bioluminescent imaging (BLI) images of three mice implanted with radiotherapy hydrogels (right), chemotherapy (middle), control (left) at day 27 post-implantation.[39]
Employed sensitive hydrogels for cancer drug delivery systemsa
| Hydrogel | Drug | Sensitivity | Cancer | Reference |
|---|---|---|---|---|
| PPZ | Silibinin | Thermosensitive | Colon |
|
| PEG-FA, PPLL | ME, 5-FU | pH-sensitive | Colon |
|
| PLGA-PEG-PLGA/CND | DOX | Thermosensitive | Prostate |
|
| Dgel AuNP | DOX | Photosensitive | Melanoma |
|
| PEG-DMA | TMZ | Photosensitive | Glioblastoma |
|
| Poloxamer P407, Poloxamer P188 | PTX | Thermosensitive | Pancreatic |
|
| Akt1 shRNA, PTX | CLA-coupled poloxamer/PEI- | Thermosensitive | Breast |
|
| PEG NPs | DOX, curcumin | pH-sensitive | Hepatocellular carcinoma |
|
| PEG-PCL-PEG/MPEG-PCL | DDP, PTX | Thermosensitive | Lung |
|
| P407, P188, graphene oxide/CS | DTX | pH/temperature | Sarcoma |
|
poly(organophosphazene): PPZ; aldehyde-functionalized four-arm PEG: PEG-FA; 4-arm PEG-b-poly(lysine): PPLL; metformin: ME; 5-fluorouracil: 5-FU; poly(lactide-co-glycolide): PLGA; polyethylene glycol: PEG; clay nano-disk: CND; paclitaxel: PTX; conjugated linolenic acid: CLA; poloxamer 407: P407; poloxamer 188: P188; polyethylenimine – PEG diacrylate: PEI-alt-PEG; PEG nanoparticles: PEG NPs; PEG-poly(3-caprolactone)-PEG: PEG-PCL-PEG; monomethoxy PEG-poly(3-caprolactone): MPEG-PCL; DNA hydrogel: Dgel; gold nanoparticles: AuNP; temozolomide: TMZ; PEG dimethacrylate: PEG-DMA; chitosan: CS.
Fig. 3(A) Effect of the presence of SWNTs in the peptide hydrogel on cell behavior.[152] (B) Tumor resistance against drugs. (C) Hypoxic cancer cell: (a) lack of oxygen in tumor site, (b) hydrogels as cell culture media can provide enough oxygen to the tumor site.
Fig. 4(A) Employing hydrogels loaded with nanoparticles for boosting magnetic hyperthermia. (B) Scaffold/hydrogel having practical photothermal effects. (C) Confocal microscopy of HCC70 cells cultured in monolayer and hydrogel environments. (a_c) In monolayer culture, (d_f) In hydrogel environment.[178]
Fig. 5(a) TDDS patch, (b) structure of a TDD patch, (c) drug diffusion within the skin's capillary system, (d) SEM images of 3D printed microneedles (MN) with different shapes.[18]
Fig. 6Using a 3D-printed lead shield during radiotherapy for facial skin cancer.[184]
Fig. 7(A) Using 3D printing to make a suitable scaffold (hydrogel) to place in chips to monitor cell reaction and functionality in different conditions. (B) Schematic diagram of lung-on-a-chip: (A) a cross-section of the microfluidic chip with human lung epithelial tumor cells (cultured on the upper surface of a porous membrane). (B) confocal fluorescence micrograph of a cross-section of the assembled chip when cells were cultured for 7 days without breathing motions (scale bar, 200 μm).[207]